Advertisement

Inflammation and Cancer

The role of the immune response and angiogenesis
  • Angus G. Dalgleish
  • Ken O’Byrne
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 130)

Abstract

The link with chronic inflammation and cancer has been recognized for certain cancers for several decades. However, only recently has the biology of chronic inflammation begun to be understood, to the point that it may play a major role in tumour development. The biology of chronic inflammation has many similarities with that of wound healing. In particular, local cell mediated immunity is attenuated and angiogenesis is increased along with other growth factors. When present long term, this provides the ideal environment for mutated cells to be nurtured and escape immune surveillance. It is of note that this process still appears to take two or three decades, as witnessed by the close association between chronic ulcerative colitis and colon cancer as well as chronic hepatitis and hepatocellular carcinoma. Closer study of the inflammatory pathways show the close interaction with apoptosis and antiapoptotic pathways, as well as the main tumour suppressor genes, such as p53, as well as a number of growth factors, such as the insulin-like growth factor. A full study of these processes reveals that there are key molecules in these pathways which may provide therapeutic as well as anti-inflammatory targets.

Keywords

Vascular Endothelial Growth Factor Epstein Barr Virus Human Papilloma Virus Cervical Intraepithelial Neoplasia Acquire Immune Deficiency Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

11. References

  1. Akagi Y. et al. (1998). Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res. 58: 4008–4014.PubMedGoogle Scholar
  2. Akiyoshi, F. et al. (1998). Serum vascular endothelial growth factor levels in various liver diseases. Dig. Dis. Sci.: 43: 41–45.PubMedGoogle Scholar
  3. al-Saleh, W. et al. (1998). Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix. J. Pathol.: 184: 283–290.PubMedGoogle Scholar
  4. Anttila, T. et al. (2001). Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 285: 47–51.PubMedGoogle Scholar
  5. Asselin-Paturel, C. et al. (1998). Quantative analysis of Th1, Th2 and TGF-beta 1 cytokine expression in tumour, TIL and PBL of non-small cell lung cancer patients. Int. J. Cancer 77: 7–12.PubMedGoogle Scholar
  6. Aziz, M. et al. (1998). Evaluation of cell-mediated immunity and circulating immune complexes as prognostic indicators in cancer patients. Cancer Detect. Prev. 22: 87–99.PubMedGoogle Scholar
  7. Baron, J. A. et al. (2003). A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348: 891–899.PubMedGoogle Scholar
  8. Bartlett, J.B.et al. (2004). The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer4: 314–322.PubMedGoogle Scholar
  9. Beraud, C. et al. (1999). Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-κB activation. Proc. Natl Acad. Sci. U.S.A. 96: 429–434.PubMedGoogle Scholar
  10. Bielefeldt-Ohmann, H. et al. (1996). Molecular pathobiology and immunology of malignant mesothelioma. J. Pathol. 178: 369–378.PubMedGoogle Scholar
  11. Bonnet, M. et al. (1999). Detection of Epstein-Barr virus in invasive breast cancers. J. Natl Cancer Inst. 91: 1376–1381.PubMedGoogle Scholar
  12. Bontkes, H.J. et al. (1999). Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J. Gen. Virol.: 80: 2453–2459.PubMedGoogle Scholar
  13. Brooks, L.A.et al. (1997). Kaposi’s sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV8)-a new human tumour virus. J. Pathol.182: 262–265.PubMedGoogle Scholar
  14. Browning, M.J. and Bodmer, W.F. (1992). MHC antigens and cancer: implications for T-cell surveillance. Curr. Opin. Immunol. 4: 613–618.PubMedGoogle Scholar
  15. Browning, M.J. and Dalgleish, A.G. (1996). ‘Introduction and historical perspective’ in Tumour Immunology, Sikora, K., Dalgleish, A.G. and Browning, M. (eds). Cambridge University Press, London.Google Scholar
  16. Buckman, S.Y. et al. (1998). COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 19: 723–729.PubMedGoogle Scholar
  17. Butt, AJ. et al. (2000). Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J. Biol Chem. 275: 39174–39181.PubMedGoogle Scholar
  18. Cacciarelli, T.V. et al. (1996). Immunoregulatory cytokines in chronic hepatitis C virus infection: pre-and posttreatment with interferon alpha. Hepatology 24: 6–9.PubMedGoogle Scholar
  19. Cainzos, M. (1989). Anergy in patients with gastric cancer. Hepatogastroenterol. 36: 36–39.Google Scholar
  20. Carbone, M. (1999). Simian virus 40 and human tumors: It is time to study mechanisms. J. Cell Biochem. 76: 189–193.PubMedGoogle Scholar
  21. Cardone, M.H. et al. (1998). Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318–1321.PubMedGoogle Scholar
  22. Carreno, V. and Quiroga, J.A. (1997). Biological properties of interleukin-12 and its therapeutic use in persistent hepatitis B virus and hepatitis C virus infection. J. Viral Hepatitis 4(Suppl. 2): 83–86.Google Scholar
  23. Casaco, A.et al. (2004). Effect of an EGF-cancer vaccine on wound healing and inflammation models. J. Surg. Res.122: 130–134.PubMedGoogle Scholar
  24. Castelao, J.E. et al. (2000). Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br. J. Cancer 82: 1364–1369.PubMedGoogle Scholar
  25. Cerqueira, E.M. et al. (1998). Genetic damage in exfoliated cells of the uterine cervix. Association and interaction between cigarette smoking and progression to malignant transformation? Acta Cytol. 42: 639–649.PubMedGoogle Scholar
  26. Chan, J.M. et al. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563–566.PubMedGoogle Scholar
  27. Chang, Y.E. and Laimins, L.A. (2000). Microarray analysis identifies interferoninducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol. 74: 4174–4182.PubMedGoogle Scholar
  28. Chen, E.K. et al. (1998). Not just another meeting: the coming of age of JAKs and STATs. Immunol. Today, 19: 338–341.PubMedGoogle Scholar
  29. Chen, Y.M. et al. (1997). Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients. Chest 112: 960–966.PubMedGoogle Scholar
  30. Clavel, C. et al. (2000). Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions. Diagn. Mol. Pathol. 9: 145–150.PubMedGoogle Scholar
  31. Coffey, D.S. (1998). Self-organization, complexity and chaos: the new biology for medicine. Nat. Med. 4: 882–885.PubMedGoogle Scholar
  32. Coffey, R.J. et al. (1997). Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc. Natl Acad. Sci. U.S.A. 94: 657–662.PubMedGoogle Scholar
  33. Cordon-Cardo, C. and Prives, C. (1999). At the crossroads of inflammation and tumorigenesis. J. Exp. Med. 190: 1367–1370.PubMedGoogle Scholar
  34. Dalgleish, A. (1999). The relevance of non-linear mathematics (chaos theory) to the treatment of cancer, the role of the immune response and the potential for vaccines. QJM 92: 347–359.PubMedGoogle Scholar
  35. Dalgleish, A.G. (1991). Viruses and cancer. Br. Med. Bull. 47: 21–46.PubMedGoogle Scholar
  36. Dameron, K.M. et al. (1994). The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb. Symp. Quant. Biol. 59: 483–489.PubMedGoogle Scholar
  37. Das, T. et al. (1999). Induction of cell proliferation and apoptosis: dependence on the dose of the inducer. Biochem. Biophys. Res. Commun. 260: 105–110.PubMedGoogle Scholar
  38. de Fraipont, F. et al. (2000). Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J. Clin. Endocrinol. Metab. 85: 4734–4741.PubMedGoogle Scholar
  39. De Luca, A. et al. (1997). The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat. Med. 3: 913–916.PubMedGoogle Scholar
  40. De Marzo, A.M. et al. (1999). New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology 53: 29–39; discussion 39–42.PubMedGoogle Scholar
  41. De The, G. (1993) The etiology of Burkitt’s lymphoma and the history of shaken dogmas. Blood Cells 19: 667–675.PubMedGoogle Scholar
  42. de Visser, K.E. and Coussens, L.M. (2005). The interplay between innate and adaptive immunity regulates cancer development. Cancer Immunol. Immunother in press.Google Scholar
  43. de Visser, K.E.et al. (2005). De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell7: 411–423.PubMedGoogle Scholar
  44. del Peso, L. et al. (1997). Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687–689.PubMedGoogle Scholar
  45. Della Bella, S. et al. (1997). Differential effects of cyclo-oxygenase pathway metabolites on cytokine production by Tlymphocytes. Prostaglandins Leukot. Essent. Fatty Acids 56: 177–184.PubMedGoogle Scholar
  46. Di Popolo, A. et al. (2000). IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 19: 5517–5524.PubMedGoogle Scholar
  47. Doherty, P.C. et al. (1994). Evasion of host immune responses by tumours and viruses. Ciba Found. Symp. 187: 245–256.PubMedGoogle Scholar
  48. D’Orazio, T.J. and Niederkon, J.Y. (1998). A novel role for TGF-beta and IL-10 in the induction of immune privilege. J. Immunol. 160: 2089–2098.PubMedGoogle Scholar
  49. Dunn, S.E. (2000). Insulin-like growth factor I stimulates angiogenesis and the production of vascular endothelial growth factor. Growth Horm. IGF Res. 10Suppl A: S41–S42.PubMedGoogle Scholar
  50. Dvorak, H.F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med.315: 1650–1659.PubMedGoogle Scholar
  51. Elahi, M.M.et al. (2005). The systemic inflammatory response predicts overall and cancer specific survival in patients with malignant lymphoma. Med. Sci. Monit.11: CR75–CR78.PubMedGoogle Scholar
  52. Eliopoulos, A.G. et al. (1999). Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J. Biol. Chem. 274: 16085–16096.PubMedGoogle Scholar
  53. Ellouk-Achard, S. et al. (1998) Induction of apoptosis in rat hepatocarcinoma cells by expression of IGF-I antisense c-DNA. J Hepatol. 29: 807–818.PubMedGoogle Scholar
  54. El-Assal, O.N. et al. (1998). Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27: 1554–1562.PubMedGoogle Scholar
  55. El-Bayoumy, K. et al. (1999). Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-lbutanone: the impact of a high-fat diet. Cancer Res. 59: 1400–1403.PubMedGoogle Scholar
  56. Faux, S.P. et al. (2000). Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres. Carcinogenesis 21: 2275–2280.PubMedGoogle Scholar
  57. Faux, S.P. et al. (2001). EGFR induced activation of NF-κB in mesothelial cells by asbestos is important in cell survival. Proc. Am. Assoc. Cancer Res. abstract 1315.Google Scholar
  58. Ferre, F. et al. (1995). Viral load in peripheral blood mononuclear cells as surrogate for clinical progression. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10: S51–S56.PubMedGoogle Scholar
  59. Fischer, S.M. et al. (1999). Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol. Carcinog. 25: 231–240.PubMedGoogle Scholar
  60. Fisseler-Eckhoff, A. et al. (1996). Neovascularisation in hyperplastic, metaplastic and potentially preneoplastic lesions of the bronchial mucosa. Virchows Arch. 429: 95–100.PubMedGoogle Scholar
  61. Fontanini, G. et al. (1996). Neoangiogenesis: a putative marker of malignancy in nonsmall cell lung cancer (NSCLC) development. Int. J. Cancer 67: 615–619.PubMedGoogle Scholar
  62. Fleming, S. (1999). Renal cancer genetics: von Hippel Lindau and other syndromes. Int. J. Dev. Biol. 43: 469–471.PubMedGoogle Scholar
  63. Folkman, J. (1995). Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333: 1757–1763.PubMedGoogle Scholar
  64. Forni, G. and Foa, R. (1996). ‘The role of cytokines in tumor rejection’ in Tumour Immunology: Immunotherapy and Cancer Vaccines. Dalgleish A.G. and Browning M (eds) Cambridge University Press: 199–218.Google Scholar
  65. Franchimont, N. et al. (1997). Interleukin-6 with its soluble receptor enhances the expression of insulin-like growth factor-I in osteoblasts. Endocrinology 138: 5248–5255.PubMedGoogle Scholar
  66. Funkhouser, E.M. and Sharp, G.B. (1995). Aspirin and reduced risk of esophageal carcinoma. Cancer 76: 1116–1119.PubMedGoogle Scholar
  67. Gabrilovich, D.I. et al. (1999). Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5: 2963–2970.PubMedGoogle Scholar
  68. Gallucci, R.M. et al. (2000). Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J. 14: 2525–2531.PubMedGoogle Scholar
  69. Ganss, R. and Hanahan, D. (1998). Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res. 58: 4673–4681.PubMedGoogle Scholar
  70. Garrido, F. et al. (1993). Natural history of HLA expression during tumour development. Immunol. Today 14: 491–499.PubMedGoogle Scholar
  71. Giovannucci, E. et al. (1995). Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333: 609–614.PubMedGoogle Scholar
  72. Giovannucci, E. et al. (1994). Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. 121: 241–246.PubMedGoogle Scholar
  73. Gjertsen, M.K. et al. (1997). Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int. J. Cancer 72: 784–790.PubMedGoogle Scholar
  74. Glinghammar, B. and Rafter, J. (2001). Colonic luminal contents induce cyclooxygenase 2 transcription in human colon carcinoma cells. Gastroenterology 120: 401–410.PubMedGoogle Scholar
  75. Gorter, A. and Meri, S. (1999). Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol. Today20: 576–582.PubMedGoogle Scholar
  76. Grange, J.M. et al. (1995). Tuberculosis and cancer: parallels in host responses and therapeutic approaches? Lancet 345: 1350–1352.PubMedGoogle Scholar
  77. Greenberg, P.D. (1991). Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol 49: 281–355.PubMedGoogle Scholar
  78. Grinwich, K.D. and Plescia, O.J. (1977). Tumor-mediated immunosuppression: prevention by inhibitors of prostaglandin synthesis. Prostaglandins 14: 1175–1182.PubMedGoogle Scholar
  79. Guillou, L. et al. (1996). Germ cell tumors of the testis overexpress wild-type p53. Am. J. Pathol. 149: 1221–1228.PubMedGoogle Scholar
  80. Hankinson, S.E. et al. (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393–1396.PubMedGoogle Scholar
  81. Harris, R.E.et al. (2005). Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol. Rep.13: 559–583.PubMedGoogle Scholar
  82. Heeschen, C. et al. (2001). Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat. Med. 7: 775–777.Google Scholar
  83. Heriot, A.G. et al. (2000). Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br. J. Cancer 82: 1009–1012.PubMedGoogle Scholar
  84. Hida, T. et al. (1998). Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res. 18: 775–782.PubMedGoogle Scholar
  85. Hildenbrand, R. et al. (1998). Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast. Lab Invest. 78: 59–71.PubMedGoogle Scholar
  86. Hildesheim, A.et al. (1997). Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease. Cancer Epidemiol. Biomarkers Prevention6: 807–813.Google Scholar
  87. Hojo, M. et al. (1999). Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397: 530–534.PubMedGoogle Scholar
  88. Hong, S.H. et al. (2000). Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J., 14: 1499–1507.PubMedGoogle Scholar
  89. Hopfl, R. et al. (2000). Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 356: 1985–1986.PubMedGoogle Scholar
  90. Horikawa, T. et al. (2000). Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 9: 715–723.Google Scholar
  91. Hrouda, D. et al. (1998). Immunotherapy of advanced prostate cancer: a phase I/II trial using mycobacterium vaccae. Br. J. Urol. 82: 568–573.PubMedGoogle Scholar
  92. Hsieh, C.Y., You, S.L., Kao, C.L. and Chen, C.J. (1999). Reproductive and infectious risk factors for invasive cervical cancer in Taiwan. Anticancer Res. 19: 4495–4500.PubMedGoogle Scholar
  93. Hu, H.M. et al. (1998). Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol. 16: 3033–3041.Google Scholar
  94. Huang, M. et al. (1998). Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 58: 1208–1216.PubMedGoogle Scholar
  95. Huang, R.P. et al. (1996) UV activates growth factor receptors via reactive oxygen intermediates. J. Cell Biol. 133: 211–220.PubMedGoogle Scholar
  96. Huang, Y.T. et al. (1999). Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD4+ T cells. Cancer Res. 59: 1599–1605.PubMedGoogle Scholar
  97. Hudson, J.D. et al. (1999). A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190: 1375–1382.PubMedGoogle Scholar
  98. Igncy, F.H. and Krammer, P.H. (2005). Tumor counterattack: fact or fiction? Cancer Immunol. Immunother. in press.Google Scholar
  99. Irani, J. et al. (1999). High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 54: 467–472.PubMedGoogle Scholar
  100. Jacobs, N. et al. (1998). Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of the uterine cervix. Clin. Exp. Immunol. 111: 219–224.PubMedGoogle Scholar
  101. Jamicson, N.B.et al. (2005). Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br. J. Cancer92: 21–23.Google Scholar
  102. Janssen, Y.M. et al. (2000). Asbestos causes translocation of p65 protein and increases NF-kappaB DNA binding activity in rat lung epithelial and pleural mesothelial cells. Am. J. Pathol. 151: 389–401.Google Scholar
  103. Jarnicki, A.G. et al. (1996). Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma. Cancer Lett. 15: 1–9.Google Scholar
  104. Jinno, K. et al. (1998). Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J. Gastroenterol. 33: 376–382.PubMedGoogle Scholar
  105. Johnston-Early, A. et al. (1983). Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. Cancer 52: 1395–1400.PubMedGoogle Scholar
  106. Jost, M. et al. (2001). Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. J. Biol. Chem. 276: 6320–6326.PubMedGoogle Scholar
  107. Kakumu, S. et al. (1997). Production of interleukins 10 and 12 by peripheral blood mononuclear cells (PBMC) in chronic hepatitis C virus (HCV) infection. Clin. Exp. Immunol. 108: 138–143.PubMedGoogle Scholar
  108. Kano, A. et al. (1999). IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem. Biophys. Res. Commun. 257: 672–677.PubMedGoogle Scholar
  109. Kaplan, M.H. et al. (1998). A signal transducer and activator of transcription (Stat)4-independent pathway for the development of T helper type 1 cells. J. Exp. Med. 188: 1191–1196.PubMedGoogle Scholar
  110. Keith, R.L. et al. (2000). Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin. Cancer Res. 6: 1616–1625.PubMedGoogle Scholar
  111. Kieser, A. et al. (1994). Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9: 963–969.PubMedGoogle Scholar
  112. Kiessling, R. et al. (2000). Have tumor cells learnt from microorganisms how to fool the immune system? Escape from immune surveillance of tumors and microorganisms: emerging mechanisms and shared strategies. Mol. Med. Today 6: 344–346.PubMedGoogle Scholar
  113. Kirk, G.R. and Clements, W.D. (1999). Crohn’s disease and colorectal malignancy. Int. J. Clin. Pract. 53: 314–315.PubMedGoogle Scholar
  114. Kitagawa, N. et al. (2000). Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt’s lymphoma growth through interleukin-10 induction. EMBO J. 19: 6742–50.PubMedGoogle Scholar
  115. Kodelja, V. et al. (1997). Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology 197: 478–493.PubMedGoogle Scholar
  116. Konturek, S.J.et al. (2000). Helicobacter pylori infection delays healing of ischaemia-reperfusion induced gastric ulcerations: new animal model for studying pathogenesis and therapy of H. pylori infection. Eur. J. Gastroenterol. Hepatol.12: 1299–313.PubMedGoogle Scholar
  117. Koshiba, T. et al. (1999). Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int. J. Pancreatol. 26: 69–76.PubMedGoogle Scholar
  118. Ladetto, M.et al. (2005). Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood105: 4784–91.PubMedGoogle Scholar
  119. Lafarge-Frayssinet, C. et al. (1997). Antisense insulin-like growth factor I transferred into a rat hepatoma cell line inhibits tumorigenesis by modulating major histocompatibility complex I cell surface expression”. Cancer Gene Ther. 4: 276–285.PubMedGoogle Scholar
  120. Lala, P.K. et al. (1997). Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int. J. Cancer 73: 371–380.PubMedGoogle Scholar
  121. Lang, J.M. et al. (1980). Delayed cutaneous hypersensitivity testing in untreated Hodgkin’s disease using a standardised new device. Biomedicine 33: 62–64.PubMedGoogle Scholar
  122. Langman, M.J. et al. (2000). Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. Br. Med. J. 320: 1642–1646.Google Scholar
  123. Lawlor MA and Rotwein P. (2000). Insulin-like growth factor-mediated muscle cell survival: central roles for Akt and cyclin-dependent kinase inhibitor p21. Mol. Cell Biol. 20: 8983–8995.PubMedGoogle Scholar
  124. Lee, J. et al. (1998). Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res. 58: 1478–1485.PubMedGoogle Scholar
  125. Lee, P.P. et al. (1997). T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood 90: 1611–1617.PubMedGoogle Scholar
  126. Lehrer, S.et al. (2005). C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int.95: 961–962.PubMedGoogle Scholar
  127. Leri, A. et al. (1999) “Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis. Am. J. Pathol. 154: 567–580.PubMedGoogle Scholar
  128. Liu, M.Y. et al. (2000). Expression of the Epstein-Barr virus BHRF1 gene, a homologue of Bcl-2, in nasopharyngeal carcinoma tissue. J. Med. Virol. 61: 241–250.PubMedGoogle Scholar
  129. Luca, M. et al. (1997). Expression of interleukin-8 by human melanoma cells upregulates MMP-2 activity and increases tumor growth and metastasis. Am. J. Pathol. 151: 1105–1113.PubMedGoogle Scholar
  130. Luxton, J.C. et al. (1997). Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls. J. Gen. Virol. 78: 917–923.PubMedGoogle Scholar
  131. Ma, J. et al. (1999). Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl Cancer Inst. 91: 620–625.PubMedGoogle Scholar
  132. Madrid, L.V. et al. (2001). Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-{kappa}B through utilization of the IκB kinase and activation of the mitogen activated protein kinase p38. J. Biol. Chem. 276: 18934–18940.PubMedGoogle Scholar
  133. Mahmud, S.et al. (2004). Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br. J. Cancer90: 93–99.PubMedGoogle Scholar
  134. Malaguarnera, M. et al. (1997). Serum interleukin 6 concentrations in chronic hepatitis C patients before and after interferon-alpha treatment. Int. J. Clin. Pharmacol Ther. 35: 385–388.PubMedGoogle Scholar
  135. Maraveyas, A. et al. (1999). Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann. Oncol. 10: 817–824.PubMedGoogle Scholar
  136. Markham, A.F. (1996). Carcinoma of the lung: warts and all. Thorax 51: 878–879.PubMedGoogle Scholar
  137. Mauray, S. et al. (2000). Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6. Eur. J. Immunol. 30: 2065–2073.PubMedGoogle Scholar
  138. Mayne, S.T. et al. (1999). Previous lung disease and risk of lung cancer among men and women nonsmokers. Am. J. Epidemiol. 149: 13–20.PubMedGoogle Scholar
  139. Mazzanti, R. et al. (1997). Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis Hepatology 25: 229–234.PubMedGoogle Scholar
  140. McGinty, A. et al. (2000). Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells. J. Biol Chem. 275: 12095–12101.PubMedGoogle Scholar
  141. Meert, K.L. et al. (1996). Elevated transforming growth factor-beta concentration correlates with post-trauma immunosuppression. J. Trauma 40: 901–906.PubMedGoogle Scholar
  142. Melief, C.J. and Kast, W.M. (1991). Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms. Semin. Cancer Biol. 2: 347–354.PubMedGoogle Scholar
  143. Mestre, J.R. et al. (1999). Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Ann. N.Y. Acad. Sci. 889: 62–71.PubMedGoogle Scholar
  144. Milich, D.R. et al. (1998). The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J. Immunol. 160: 2013–2021.PubMedGoogle Scholar
  145. Mizoguchi, H. et al. (1992). Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258: 1795–1798.PubMedGoogle Scholar
  146. Molina, M.A. et al. (1999). Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 59: 4356–4362.PubMedGoogle Scholar
  147. Moller, H. et al. (1994). Obesity and cancer risk: a Danish record-linkage study. Eur. J. Cancer 30A: 344–350.PubMedGoogle Scholar
  148. Monson, R.R. et al. (1976). Chronic mastitis and carcinoma of the breast. Lancet 2: 224–226.PubMedGoogle Scholar
  149. Moore, R.J. et al. (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 5: 828–831.PubMedGoogle Scholar
  150. Moriguchi, S. et al. (1998). Exercise training restores decreased cellular immune functions in obese Zucker rats. J. Appl. Physiol. 84: 311–317.PubMedGoogle Scholar
  151. Mosmann, T.R. and Coffman, R.L. (1989). TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7: 145–173.PubMedGoogle Scholar
  152. Murata, H. et al. (1999). Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am. J. Gastroenterol. 94: 451–455.PubMedGoogle Scholar
  153. Nabel, G.J. (1999). A transformed view of cyclosporine. Nature 397: 471–472.PubMedGoogle Scholar
  154. Nakata, S. et al. (1993). Study of risk factors for prostatic cancer. Hinyokika Kiyo 39: 1017–1024. Discussion: 1024–1025.PubMedGoogle Scholar
  155. Nees, M. et al. (2001). Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaBresponsive genes in cervical keratinocytes. J. Virol. 75: 4283–4296.PubMedGoogle Scholar
  156. Nelson, W.G.et al. (2004). The role of inflammation in the pathogenesis of prostate cancer. J. Urol.172: S6–S11. Discussion: S11–S12.PubMedGoogle Scholar
  157. O’Byrne, K.J. et al. (2000a). The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur. J. Cancer. 36: 151–169.PubMedGoogle Scholar
  158. O’Byrne, K.J. et al. (2000b). Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer. Br. J. Cancer 82: 1427–1432.PubMedGoogle Scholar
  159. O’Hara, R.J. et al. (1998). Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin. Cancer Res. 4: 1943–1948.PubMedGoogle Scholar
  160. O’Sullivan, G.C.et al. (1996). Regional immunosuppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes. J. Immunol.157: 4717–4720.PubMedGoogle Scholar
  161. Oka, M. et al. (1992). Immunosuppression in patients with Barrett’s esophagus. Surgery 112: 11–17.PubMedGoogle Scholar
  162. Olaitan, A. et al. (1998). Changes to the cytokine microenvironment in the genital tract mucosa of HIV+ women. Clin. Exp. Immunol. 112: 100–104.PubMedGoogle Scholar
  163. Paganini-Hill, A. (1994). Aspirin and the prevention of colorectal cancer: a review of the evidence. Semin. Surg. Oncol. 10: 158–164.PubMedGoogle Scholar
  164. Pamphilon, D.H. et al. (1991). Immunomodulation by ultraviolet light: clinical studies and biological effects. Immunol. Today 12: 119–123.PubMedGoogle Scholar
  165. Papadopoulos, E.B. et al. (1994). Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl. J. Med. 330: 1185–1191.PubMedGoogle Scholar
  166. Pass, H.I. et al. (1996). Inhibition of hamster mesothelioma tumorigenesis by an antisense expression plasmid to the insulin-like growth factor-I receptor. Cancer Res. 56: 4044–4048.PubMedGoogle Scholar
  167. Penn, I. (1988). Tumors of the immunocompromised patient. Annu. Rev. Med. 39: 63–73.PubMedGoogle Scholar
  168. Pepper, M.S. et al. (1993). Biphasic effect of transforming growth factor factor-beta 1 on in vitro angiogenesis. Exp. Cell Res. 204: 356–363.PubMedGoogle Scholar
  169. Pettit, S.J. et al. (2000). Immune selection in neoplasia: towards a microevolutionary model of cancer development. Br. J. Cancer 82: 1900–1906.PubMedGoogle Scholar
  170. Peus, D. et al. (2000). UVB-induced epidermal growth factor receptor phosphorylation is critical for downstream signaling and keratinocyte survival. Photochem. Photobiol. 72: 135–140.PubMedGoogle Scholar
  171. Pianetti, S. et al. (2001). Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpein-mediated degradation of IkappaB-alpha that can be inhibited by the tumour suppressor PTEN. Oncogene 20: 1287–1299.PubMedGoogle Scholar
  172. Piccinni, M.P. et al. (1998). Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat. Med. 4: 1020–1024.PubMedGoogle Scholar
  173. Prince, M.M. and Hildreth, N.G. (1986). The influence of potential biases on the risk of breast tumors among women who received radiotherapy for acute postpartum mastitis. J. Chronic. Dis. 39: 553–560.PubMedGoogle Scholar
  174. Qin, L. et al. (1996). Gene transfer of transforming growth factor-beta 1 prolongs murine cardiac allograft survival by inhibiting cell mediated immunity. Human. Gene Ther. 7: 1981–1988.Google Scholar
  175. Richards, J.S. et al. (1995). Ovarian cell differentiation: a cascade of multiple hormones, cellular signals, and regulated genes. Recent Prog. Horm. Res. 50: 223–254.PubMedGoogle Scholar
  176. Richtsmeier W.J. and Eisele, D. (1986). In vivo anergy reversal with cimetidine in patients with cancer. Arch. Otolaryngol. Head and Neck Surg. 112: 1074–1077.Google Scholar
  177. Roman, C. et al. (2001) TGF-beta and colorectal carcinogenesis. Microsc. Res. Tech. 52: 450–457.PubMedGoogle Scholar
  178. Rook, G.A. et al. (1994). Hormones, peripherally activated prohormones and regulation of the Th1/Th2 balance. Immunol. Today 15: 301–303.PubMedGoogle Scholar
  179. Rooney, C.M. et al. (1995). Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345: 9–13.PubMedGoogle Scholar
  180. Rosenberg, S.A. et al. (1986). A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318–1321.PubMedGoogle Scholar
  181. Roses, D.F. et al. (1979). Malignant melanoma. Delayed hypersensitivity skin testing. Arch. Surg. 114: 35–38.PubMedGoogle Scholar
  182. Rubini, M. et al. (1994). Platelet-derived growth factor increases the activity of the promoter of the insulin-like growth factor-I (IGF-I) receptor gene. Exp. Cell Res. 211: 374–379.PubMedGoogle Scholar
  183. Saareks, V. et al. (1998). Nicotine stereoisomers and cotinine stimulate prostaglandin E2 but inhibit thromboxane B2 and leukotriene E4 synthesis in whole blood. Eur. J. Pharmacol. 353: 87–92.PubMedGoogle Scholar
  184. Saha, D. et al. (1999). Synergistic induction of cyclooxygenase-2 by transforming growth factor-betal and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia 1: 508–517.PubMedGoogle Scholar
  185. Sairam, M. et al. (1998). Effect of hypobaric hypoxia on immune function in albino rats. Int. J. Biometeorol. 42: 55–59.PubMedGoogle Scholar
  186. Salgado, R. et al. (1999). Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br. J. Cancer 80: 892–897.PubMedGoogle Scholar
  187. Salvadori, S. et al. (1994). Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2 secreting tumors. J. Immunol. 153: 5176–5182.PubMedGoogle Scholar
  188. Savanthanan, S. and O’Byrne, K.J. (2001). Antiestrogens. J. Br. Meno. Soc. 7: 21–26.Google Scholar
  189. Sawaoka, H. et al. (1998a). Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins Leukot. Essent. Fatty Acids 59: 313–316.PubMedGoogle Scholar
  190. Sawaoka, H. et al. (1998b). Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol. 274: G1061–G1067.PubMedGoogle Scholar
  191. Sawaoka, H. et al. (1999). Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab. Invest. 79: 1469–1477.PubMedGoogle Scholar
  192. Schaffer, M. and Barbul, A. (1998). Lymphocyte function in wound healing and following injury. Br. J. Surg. 85: 444–460.PubMedGoogle Scholar
  193. Schreinemachers, D.M. and Everson, R.B. (1994). Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138–146.PubMedGoogle Scholar
  194. Schror, K. et al. (1998). Augmented myocardial ischaemia by nicotine-mechanisms and their possible significance. Br. J. Pharmacol. 125: 79–86.PubMedGoogle Scholar
  195. Singer, A.J. and Clark, R.A. (1999). Cutaneous wound healing. N. Engl. J. Med. 341: 738–746.PubMedGoogle Scholar
  196. Sonnex, C. (1998). Human papillomavirus infection with particular reference to genital disease. J. Clin. Pathol. 51: 643–648.PubMedGoogle Scholar
  197. Sparmann A. and Bar-Sagi D. (2005). Ras oncogene and inflammation: partners in crime. Cell Cycle4 in press.Google Scholar
  198. Spivak, M. et al. (1999). Interrelation of lymphocyte subpopulations in peripheral blood under cervical papillomavirus infection. Folia Microbiol. 44: 721–725.Google Scholar
  199. Strand, S. and Galle, P.R. (1998). Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol. Med. Today 4: 63–68.PubMedGoogle Scholar
  200. Sredni, B. et al. (1996). Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101. J. Natl. Cancer Inst. 88: 1276–1284.PubMedGoogle Scholar
  201. Study, C.P. (1992). The American Cancer Society Prospective Study. Stat. Bull. Metrop. Insur. Co. 73: 21–29.Google Scholar
  202. Subbaramaiah, K. et al. (1997). Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc. Soc. Exp. Biol. Med. 216: 201–210.PubMedGoogle Scholar
  203. Swede, H.et al. (2005). Association of regular aspirin use and breast cancer risk. Oncology68: 40–47.PubMedGoogle Scholar
  204. Takagi, A. et al. (2000). The effect of Helicobacter pylori on cell proliferation and apoptosis in gastric epithelial cell lines. Aliment. Pharmacol. Ther. 14: 188–192.PubMedGoogle Scholar
  205. Takada, K. (2000). Epstein-Barr virus and gastric carcinoma. Mol. Pathol. 53: 255–261.PubMedGoogle Scholar
  206. Takahashi, Y. et al. (1999). Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or-2. FEBS Lett. 460: 145–148.PubMedGoogle Scholar
  207. Taketo, M.M. (1998). Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl Cancer Inst. 90: 1609–1620.PubMedGoogle Scholar
  208. Thanos, D. and Maniatis, T. (2000). NF-κB: a lesson in family values. Cell 80: 529–532.Google Scholar
  209. Thun, M.J. and Namboodin, M.M. (1991). Aspirin use and reduced risk of fatal colon cancer. N. Eng. J. Med. 325: 1593–1596.Google Scholar
  210. Tomozawa, S. et al. (1999). Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br. J. Cancer. 81: 1274–1279.PubMedGoogle Scholar
  211. Tsai, S.L. et al. (1997). Detection of type-2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25: 449–458.PubMedGoogle Scholar
  212. Tsuji, S. et al. (1996). Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot. Essent. Fatty Acids 55: 179–183.PubMedGoogle Scholar
  213. Tsujii, M. and DuBois, R.N. (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493–501.PubMedGoogle Scholar
  214. Tsujii, M. et al. (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl Acad. Sci. U.S.A. 94: 3336–3340.PubMedGoogle Scholar
  215. Tsujii, M. et al. (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells”. Cell, 93: 705–716.PubMedGoogle Scholar
  216. Ung, A. et al. (1999). Soluble interleukin 2 receptor levels and cervical neoplasia: results from a population-based case-control study in Costa Rica. Cancer Epidemiol. Biomarkers Prev. 8: 249–253.PubMedGoogle Scholar
  217. Uotila, P. (1996). The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol. Immunother. 43: 1–9.PubMedGoogle Scholar
  218. Um, S.J. et al. (2000). Antiproliferative effects of retinoic acid/interferon in cervical carcinoma cell lines: cooperative growth suppression of IRF-1 and p53. Int. J. Cancer 85: 416–423.PubMedGoogle Scholar
  219. Vaganova, I.G. (2000). Apoptosis and proliferation of epithelial cells in papillomaviral and chlamydial cervicitis. Vopr. Onkol. 46: 578–582.PubMedGoogle Scholar
  220. Vainio, H. and Morgan, G. (1998). Cyclo-oxygenase 2 and breast cancer prevention. Non-steroidal anti-inflammatory agents are worth testing in breast cancer. Br. Med. J. 317: 828.Google Scholar
  221. Vane, J.R. et al. (1998). Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38: 97–120.PubMedGoogle Scholar
  222. Vile, R. et al. (1996). ‘Tumour Vaccines’ in Immunotherapy in Cancer. Gore, M. and Riches, P. (eds). Wiley, Chichester.Google Scholar
  223. White, R. et al. (1988). Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319: 525–32.PubMedGoogle Scholar
  224. Volpert, O.V. et al. (1997). Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 14: 1495–1502.PubMedGoogle Scholar
  225. Wahl, S.M. et al. (1987). Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc. Natl Acad. Sci. U.S.A. 84: 5788–5792.PubMedGoogle Scholar
  226. Wallenius, V. et al. (2000). Normal pharmacologically-induced, but decreased regenerative liver growth in interleukin-6-deficient (IL-6(-/-) mice. J. Hepatol. 33: 967–974.PubMedGoogle Scholar
  227. Wang, L.S. et al. (1999). Detection of Epstein-Barr virus in esophageal squamous cell carcinoma in Taiwan. Am. J. Gastroenterol. 94: 2834–2839.PubMedGoogle Scholar
  228. Wang, P.H. et al. (1998). IGF-I induction of p53 requires activation of MAP kinase in cardiac muscle cells. Biochem. Biophys. Res. Commun. 245: 912–917.PubMedGoogle Scholar
  229. Wang, X. et al. (2000). Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J. Biol. Chem. 275: 14624–14631.PubMedGoogle Scholar
  230. Watanabe, M. et al. (1997). Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Am. J. Pathol. 150: 1869–1880.PubMedGoogle Scholar
  231. Webster, N.J. et al. (1996). Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res. 56: 2781–2788.PubMedGoogle Scholar
  232. Werner, H. et al. (1996). Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl Acad. Sci. U.S.A. 93: 8318–8323.PubMedGoogle Scholar
  233. White, CD. et al. (1992). Inflammatory cell infiltrate in the cervix as a predictor of residual cervical intraepithelial neoplasia after conization. J. Reprod. Med. 37: 799–802.PubMedGoogle Scholar
  234. Williams, M.P. and Pounder, R.E. (1999). Helicobacter pylori: from the benign to the malignant. Am. J. Gastroenterol. 94: S11–S16.PubMedGoogle Scholar
  235. Wolff, H. et al. (1998). Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58: 4997–5001.PubMedGoogle Scholar
  236. Wu, X. et al. (2000). Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. J. Natl Cancer Inst. 92: 737–743.PubMedGoogle Scholar
  237. Wu, Y. et al. (1996). Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death. J. Cell Physiol. 168: 499–509.PubMedGoogle Scholar
  238. Yamamoto, T. et al. (1999). Epstein-Barr virus (EBV)-infected cells were frequently but dispersely detected in T-cell lymphomas of various types by in situ hybridization with an RNA probe specific to EBV-specific nuclear antigen 1. Virus Res. 65: 43–55.PubMedGoogle Scholar
  239. Yang, C.H. et al. (2001). IFNalpha/beta promotes cell survival by activating NF-kappaB through phosphatidyl inositol-3 kinase and Akt. J. Biol. Chem. 276: 13756–13761.PubMedGoogle Scholar
  240. Yang, T. et al. (1999). Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro. Am. J. Physiol. 277: F1–F9.PubMedGoogle Scholar
  241. Yao, R. et al. (2000). Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs’ chemopreventive efficacies in mouse lung tumorigenesis. Exp. Lung Res. 26: 731–742PubMedGoogle Scholar
  242. Yeung, M.C. and Lau, A.S. (1998). Tumor suppressor p53 as a component of the tumor necrosis factor-induced, protein kinase PKR-mediated apoptotic pathway in human promonocytic U937 cells. J. Biol. Chem. 273: 25198–25202.PubMedGoogle Scholar
  243. Zea, A.H. et al. (1995). Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1: 1327–1335.PubMedGoogle Scholar
  244. Zhang, F. et al. (1999). Curcumin inhibits cyclooxygenase-2 transcription in bile acid-and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 20: 445–451.PubMedGoogle Scholar
  245. Zheng, X. et al. (1994). Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case control study in Southern China. Acta Oncol. 33: 867–872.PubMedGoogle Scholar
  246. Zhou, B.P. et al. (2000). HER-2/neu blocks tumour necrosis factor-induced apoptosis via the Akt/NF-κB pathway. J. Biol. Chem. 275: 8027–8031.PubMedGoogle Scholar
  247. Zhu, K. et al. (1999). p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene 18: 7740–7747.PubMedGoogle Scholar
  248. zur Hausen, A. et al. (2000). Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res. 60: 2745–2748.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Angus G. Dalgleish
    • 1
  • Ken O’Byrne
    • 2
  1. 1.Division of OncologySt. George’s Hospital Medical SchoolLondonUK
  2. 2.Medical OncologySt James’s Hospital and Trinity CollegeDublinIreland

Personalised recommendations